Patents Assigned to NanoPharmaceuticals LLC
-
Patent number: 11723888Abstract: Chemical compounds/compositions, methods of synthesis, and methods of use are provided. The compounds/compositions are directed toward thyrointegrin antagonists directly conjugated to a polymer. The compounds/compositions may further comprise an additional substituent also conjugated to the polymer. The compounds/compositions may demonstrate antiangiogenic effect and efficacy against conditions, particularly cancers.Type: GrantFiled: December 9, 2021Date of Patent: August 15, 2023Assignee: NANOPHARMACEUTICALS LLCInventors: Shaker A. Mousa, Bruce A. Hay, Ozlem Ozen Karakus
-
Patent number: 11351137Abstract: Chemical compositions and methods of synthesis thereof. The compositions disclosed and described herein are directed toward thyroid hormone ?v?3 integrin receptor antagonists conjugated to targets of the norepinephrine transporter (NET) or the catecholamine transporter. The compositions have a dual targeting effect and increased targeting efficiency in the treatment and diagnostic imaging of neuroendocrine tumors.Type: GrantFiled: June 7, 2021Date of Patent: June 7, 2022Assignee: NANOPHARMACEUTICALS LLCInventors: Shaker Mousa, Mehdi Rajabi, Ozlem O. Karakus
-
Patent number: 11186551Abstract: Chemical compounds/compositions, methods of synthesis, and methods of use. The compounds/compositions are directed toward thyrointegrin antagonists conjugated to a polymer. The compounds/compositions further comprise an additional substituent also conjugated to the polymer. The compounds/compositions demonstrate increased uptake across the blood brain barrier along with increased retention therein and retention within tumor. The compounds/compositions may also include improved synthesis scalability, improved purity, improved aqueous solubility, and a solid product or intermediate. The compounds/compositions may demonstrate improved antiangiogenic effect and improved efficacy against conditions, particularly cancers, requiring blood brain barrier permeability, for example, glioblastoma (GBM).Type: GrantFiled: February 11, 2021Date of Patent: November 30, 2021Assignee: NANOPHARMACEUTICALS LLCInventors: Shaker A. Mousa, Bruce A. Hay
-
Patent number: 11077082Abstract: Chemical compositions and methods of synthesis thereof. The compositions disclosed and described herein are directed toward thyroid hormone ?v?3 integrin receptor antagonists conjugated to targets of the norepinephrine transporter (NET) or the catecholamine transporter. The compositions have a dual targeting effect and increased targeting efficiency in the treatment and diagnostic imaging of neuroendocrine tumors.Type: GrantFiled: April 30, 2019Date of Patent: August 3, 2021Assignee: NANOPHARMACEUTICALS, LLCInventors: Shaker Mousa, Mehdi Rajabi, Ozlem O. Karakus
-
Patent number: 10961204Abstract: Chemical compounds/compositions, methods of synthesis, and methods of use. The compounds/compositions are directed toward thyrointegrin antagonists conjugated to a polymer. The compounds/compositions further comprise an additional substituent also conjugated to the polymer. The compounds/compositions demonstrate increased uptake across the blood brain barrier along with increased retention therein and retention within tumor. The compounds/compositions may also include improved synthesis scalability, improved purity, improved aqueous solubility, and a solid product or intermediate. The compounds/compositions may demonstrate improved antiangiogenic effect and improved efficacy against conditions, particularly cancers, requiring blood brain barrier permeability, for example, glioblastoma (GBM).Type: GrantFiled: April 29, 2020Date of Patent: March 30, 2021Assignee: NANOPHARMACEUTICALS LLCInventors: Shaker A. Mousa, Bruce A. Hay
-
Patent number: 10695436Abstract: Chemical compositions and methods of synthesis thereof. The compositions disclosed and described herein are directed toward and classified as anti-angiogenic thyrointegrin antagonists, which may be capable of reacting with one or more cell surface receptors of the integrin ?v?3 receptor family. Anti-angiogenic thyrointegrin antagonists or derivatives thereof are conjugated via a non-cleavable linker having an amine, diamine or triazole linkage to polymers of Polyethylene Glycol, cyclodextrin, chitosan, alginic acid or hyaluronic acid, forming a single chemical entity.Type: GrantFiled: December 18, 2018Date of Patent: June 30, 2020Assignee: NANOPHARMACEUTICALS, LLCInventors: Shaker A. Mousa, Mehdi Rajabi
-
Patent number: 10328043Abstract: Chemical compositions and methods of synthesis thereof. The compositions disclosed and described herein are directed toward thyroid hormone ?v?3 integrin receptor antagonists conjugated to targets of the norepinephrine transporter (NET) or the catecholamine transporter. The compositions have a dual targeting effect and increased targeting efficiency in the treatment and diagnostic imaging of neuroendocrine tumors.Type: GrantFiled: April 11, 2018Date of Patent: June 25, 2019Assignee: NANOPHARMACEUTICALS, LLC.Inventors: Shaker Mousa, Mehdi Rajabi, Ozlem O. Karakus
-
Patent number: 10201616Abstract: Chemical compositions and methods of synthesis thereof. The compositions disclosed and described herein are directed toward and classified as anti-angiogenic thyrointegrin antagonists, which may be capable of reacting with one or more cell surface receptors of the integrin ?v?3 receptor family. Anti-angiogenic thyrointegrin antagonists or derivatives thereof are conjugated via a non-cleavable linker having an amine, diamine or triazole linkage to polymers of Polyethylene Glycol, cyclodextrin, chitosan, alginic acid or hyaluronic acid, forming a single chemical entity.Type: GrantFiled: June 7, 2017Date of Patent: February 12, 2019Assignee: NANOPHARMACEUTICALS, LLCInventors: Shaker A. Mousa, Mehdi Rajabi
-
Patent number: 10130686Abstract: Thyroid hormone antagonists and their nanoparticle formulations (Nanotetrac™ or Nanotriac™) act at a cell surface receptor to block angiogenesis and tumor cell proliferation. The complex anti-angiogenic performs actions on specific cytokines and chemokines. Thyroid hormone antagonists inhibit expression in tumor cells of cytokine genes, e.g., specific interleukins, and chemokine genes, such as fractalkine (CX3CL1), and chemokine receptor genes (CX3CR1) that are targets in the development of inflammation-suppressant drugs. This application discloses a novel composition of Tetra or Tri-iodothyroacetic acid (tetrac or triac), other thyroid partial agonists or antagonists and their nanoparticle formulations conjugated to polymers and encapsulating non-steroidal anti-inflammatory, anti-inflammatory glucocorticoids, and/or polyphenols for the management of various acute and chronic inflammatory disorders ranging from neurological, vascular, and musculoskeletal disorders.Type: GrantFiled: November 21, 2016Date of Patent: November 20, 2018Assignee: NANOPHARMACEUTICALS LLCInventors: Shaker A. Mousa, Paul J. Davis
-
Patent number: 10060934Abstract: A method for screening a patient for angioinhibition resistance and treating said patient having a disease susceptible to treatment via an anti-angiogenic agent. The screening method includes an assay for identifying the presence of angioinhibition resistance in patients by collecting patient blood or serum and subjecting it to a Chick Chorioallantoic Membrane (CAM) angiogenesis assay configured for accepting a human tumor wherein the human tumor xenograft includes a vasculature system. The screening method and assay further includes steps that include using the CAM results for identifying the endogenous pro-angiogenic non-peptide hormone concentrations of the blood sample by calculating the vascular activity of the vasculature system of the human tumor xenograft in the presence of anti-angiogenic drugs and inducing in the patient, a state of subclinical hypothyroidism prior to commencing anti-angiogenic treatment.Type: GrantFiled: November 18, 2014Date of Patent: August 28, 2018Assignee: NANOPHARMACEUTICALS LLCInventors: Shaker A. Mousa, Paul J. Davis
-
Patent number: 9980933Abstract: Disclosed are methods of treating subjects having conditions related to angiogenesis including administering an effective amount of a polymeric form of thyroid hormone, or an antagonist thereof, to promote or inhibit angiogenesis in the subject. Compositions of the polymeric forms of thyroid hormone, or thyroid hormone analogs, are also disclosed.Type: GrantFiled: August 26, 2013Date of Patent: May 29, 2018Assignee: NANOPHARMACEUTICALS LLCInventors: Shaker A. Mousa, Faith B. Davis, Paul J. Davis
-
Patent number: 9839614Abstract: Disclosed are methods of treating subjects having conditions related to angiogenesis including administering an effective amount of a polymeric nanoparticle form of thyroid hormone agonist, partial agonist or an antagonist thereof, to promote or inhibit angiogenesis in the subject. Nanoparticle forms of thyroid hormone or thyroid hormone analogs as well as uses thereof are also disclosed.Type: GrantFiled: December 22, 2015Date of Patent: December 12, 2017Assignee: NANOPHARMACEUTICALS, LLCInventors: Shaker Mousa, Paul Davis
-
Patent number: 9750709Abstract: Disclosed are methods of treating subjects having conditions related to angiogenesis including administering an effective amount of a polymeric Nanoparticle form of thyroid hormone agonist, partial agonist or an antagonist thereof, to promote or inhibit angiogenesis in the subject. Compositions of the polymeric forms of thyroid hormone, or thyroid hormone analogs, are also disclosed.Type: GrantFiled: February 20, 2014Date of Patent: September 5, 2017Assignee: NANOPHARMACEUTICALS LLCInventors: Shaker A. Mousa, Faith B. Davis, Paul J. Davis
-
Patent number: 9579300Abstract: Disclosed are methods of treating subjects having conditions related to angiogenesis including administering an effective amount of a polymeric Nanoparticle form of thyroid hormone agonist, partial agonist or an antagonist thereof, to promote or inhibit angiogenesis in the subject. Compositions of the polymeric forms of thyroid hormone, or thyroid hormone analogs, are also disclosed.Type: GrantFiled: February 20, 2014Date of Patent: February 28, 2017Assignee: NANOPHARMACEUTICALS LLCInventors: Shaker A. Mousa, Faith B. Davis, Paul J. Davis
-
Patent number: 9498536Abstract: Thyroid hormone antagonists and their nanoparticle formulations (Nanotetrac™ or Nanotriac™) act at a cell surface receptor to block angiogenesis and tumor cell proliferation. The complex anti-angiogenic performs actions on specific cytokines and chemokines. Thyroid hormone antagonists inhibit expression in tumor cells of cytokine genes, e.g., specific interleukins, and chemokine genes, such as fractalkine (CX3CL1), and chemokine receptor genes (CX3CR1) that are targets in the development of inflammation-suppressant drugs. This application discloses a novel composition of Tetra or Tri-iodothyroacetic acid (tetrac or triac), other thyroid partial agonists or antagonists and their nanoparticle formulations conjugated to polymers and encapsulating non-steroidal anti-inflammatory, anti-inflammatory glucocorticoids, and/or polyphenols for the management of various acute and chronic inflammatory disorders ranging from neurological, vascular, and musculoskeletal disorders.Type: GrantFiled: April 1, 2014Date of Patent: November 22, 2016Assignee: NANOPHARMACEUTICALS LLCInventors: Shaker A. Mousa, Paul J. Davis
-
Patent number: 9289395Abstract: Disclosed are methods of treating subjects having conditions related to angiogenesis including administering an effective amount of a polymeric Nanoparticle form of thyroid hormone agonist, partial agonist or an antagonist thereof, to promote or inhibit angiogenesis in the subject. Compositions of the polymeric forms of thyroid hormone, or thyroid hormone analogs, are also disclosed.Type: GrantFiled: November 16, 2010Date of Patent: March 22, 2016Assignee: NANOPHARMACEUTICALS LLCInventors: Paul J. Davis, Shaker A. Mousa
-
Patent number: 9272049Abstract: Provided herein are compositions and methods for preventing and treating diseases and risk factors associated with metabolic syndrome by targeting the RGD-binding site of selected intra- and extracellular proteins. Exemplary compositions include RGD-polyphenol conjugates via an ester linkage; polyphenol polymer conjugated to RGD analogs or mimetics; and RGD polymer conjugates linked to polyphenol.Type: GrantFiled: June 8, 2011Date of Patent: March 1, 2016Assignee: NANOPHARMACEUTICALS LLCInventors: Maria Alexander-Bridges, Shaker A. Mousa, Paul J. Davis
-
Patent number: 9220788Abstract: Disclosed are methods of treating subjects having conditions related to angiogenesis including administering an effective amount of a polymeric nanoparticle form of thyroid hormone agonist, partial agonist or an antagonist thereof, to promote or inhibit angiogenesis in the subject. Nanoparticle forms of thyroid hormone or thyroid hormone analogs as well as uses thereof are also disclosed.Type: GrantFiled: June 15, 2010Date of Patent: December 29, 2015Assignee: NANOPHARMACEUTICALS LLCInventors: Paul J. Davis, Faith B. Davis, Shaker A. Mousa, Gennadi V. Glinksy, Aleck Hercbergs
-
Patent number: 9198887Abstract: Disclosed are methods of treating subjects having conditions related to angiogenesis including administering an effective amount of a polymeric form of thyroid hormone, or an antagonist thereof, to promote or inhibit angiogenesis in the subject. Compositions of the polymeric forms of thyroid hormone, or thyroid hormone analogs, are also disclosed.Type: GrantFiled: November 13, 2013Date of Patent: December 1, 2015Assignee: NANOPHARMACEUTICALS LLCInventors: Shaker A. Mousa, Faith B. Davis, Paul J. Davis
-
Patent number: 9180107Abstract: Provided herein are compositions and methods for treating cancer by increasing the inhibitory effect of cetuximab on HIF1? expression by administering cetuximab in combination with anti-angiogenic thyroid hormone analogs such as tetrac or triac.Type: GrantFiled: March 31, 2010Date of Patent: November 10, 2015Assignee: NANOPHARMACEUTICALS LLCInventors: Hung-Yun Lin, Faith B. Davis, Paul J. Davis, Shaker A. Mousa